WO2009109862A3 - Substances thérapeutiques anticancéreuses améliorées - Google Patents

Substances thérapeutiques anticancéreuses améliorées Download PDF

Info

Publication number
WO2009109862A3
WO2009109862A3 PCT/IB2009/005061 IB2009005061W WO2009109862A3 WO 2009109862 A3 WO2009109862 A3 WO 2009109862A3 IB 2009005061 W IB2009005061 W IB 2009005061W WO 2009109862 A3 WO2009109862 A3 WO 2009109862A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
disclosed
approaches
therapies
biomarker
Prior art date
Application number
PCT/IB2009/005061
Other languages
English (en)
Other versions
WO2009109862A2 (fr
Inventor
Rolf Lewensohn
Lukas Orre
Janne Lehtio
Torbjörn GRÄSLUND
Original Assignee
Rolf Lewensohn
Lukas Orre
Janne Lehtio
Graeslund Torbjoern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rolf Lewensohn, Lukas Orre, Janne Lehtio, Graeslund Torbjoern filed Critical Rolf Lewensohn
Publication of WO2009109862A2 publication Critical patent/WO2009109862A2/fr
Publication of WO2009109862A3 publication Critical patent/WO2009109862A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

Des aspects de la présente invention concernent les domaines de la biologie moléculaire et de la médecine. Plus spécifiquement, la présente invention concerne plusieurs approches pour fournir à des sujets souffrant du cancer un inhibiteur de S100A6 et/ou S100A4 seul ou en combinaison avec d’autres thérapies anticancéreuses de manière à améliorer la thérapie du cancer et/ou traiter plus efficacement le cancer, en particulier des formes de cancer qui sont résistantes à d’autres thérapies. La présente invention concerne en outre des approches pour utiliser S100A6 et/ou S100A4 en tant que biomarqueur pour des métastases. De plus, la présente invention concerne des approches pour utiliser S100A6 et/ou S100A4 en tant que biomarqueur pour des thérapies anticancéreuses, en particulier en tant que biomarqueur pour déterminer les réponses individuelles à des thérapies anticancéreuses. De plus, la présente invention concerne des approches pour identifier des inhibiteurs de S100A6 et/ou S100A4, par exemple, qui agissent de manière synergique avec une thérapie anticancéreuse.
PCT/IB2009/005061 2008-03-06 2009-03-04 Substances thérapeutiques anticancéreuses améliorées WO2009109862A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3443808P 2008-03-06 2008-03-06
US61/034,438 2008-03-06
US9049808P 2008-08-20 2008-08-20
US61/090,498 2008-08-20

Publications (2)

Publication Number Publication Date
WO2009109862A2 WO2009109862A2 (fr) 2009-09-11
WO2009109862A3 true WO2009109862A3 (fr) 2009-12-03

Family

ID=40833040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/005061 WO2009109862A2 (fr) 2008-03-06 2009-03-04 Substances thérapeutiques anticancéreuses améliorées

Country Status (1)

Country Link
WO (1) WO2009109862A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132958A1 (fr) * 2009-05-22 2010-11-25 Garvan Institute Of Medical Research Procédés pour prédire la réactivité à un traitement
US20130090355A1 (en) * 2010-05-21 2013-04-11 Albert Einstein College Of Medicine Of Yeshiva University Chemical agents for the prevention of inhibition or tumor metastasis
CA2884151A1 (fr) * 2012-09-10 2014-03-13 Westfaelische Wilhelms-Universitaet Muenster Methodes et composes pour la prevention, le traitement et le diagnostic d'un etat inflammatoire
GB201219487D0 (en) 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096878A2 (fr) * 2000-06-14 2001-12-20 University Of Zurich Marqueur pour maladies neurodegeneratives et son utilisation pour le criblage de medicaments diriges contre lesdites maladies
WO2005090570A1 (fr) * 2004-03-24 2005-09-29 Supratek Pharma Inc. Compositions therapeutiques et methodes de traitement de maladies impliquant l'angiogenese
WO2007008647A2 (fr) * 2005-07-07 2007-01-18 Vanderbilt University Diagnostic et classement de gliomes a l'aide d'une approche proteomique
WO2008007073A2 (fr) * 2006-07-11 2008-01-17 Pci Biotech As Procédé

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096878A2 (fr) * 2000-06-14 2001-12-20 University Of Zurich Marqueur pour maladies neurodegeneratives et son utilisation pour le criblage de medicaments diriges contre lesdites maladies
WO2005090570A1 (fr) * 2004-03-24 2005-09-29 Supratek Pharma Inc. Compositions therapeutiques et methodes de traitement de maladies impliquant l'angiogenese
WO2007008647A2 (fr) * 2005-07-07 2007-01-18 Vanderbilt University Diagnostic et classement de gliomes a l'aide d'une approche proteomique
WO2008007073A2 (fr) * 2006-07-11 2008-01-17 Pci Biotech As Procédé

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOE S ET AL: "Photochemically induced gene silencing using small interfering RNA molecules in combination with lipid carriers", 20070701; 20070700, vol. 17, no. 2, 1 July 2007 (2007-07-01), pages 166 - 173, XP002450989 *
KATO C ET AL: "S100A4 inhibition by RNAi up-regulates osteoblast related genes in periodontal ligament cells", 31 December 2004, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, PAGE(S) 147 - 153, ISSN: 0006-291X, XP004672561 *
STEIN U ET AL: "95 POSTER Invasion knock down of human colon cancer cells by siRNA specific for S100A4, a newly identified target gene of beta-catenin/TCF signaling", 1 November 2006, EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, PAGE(S) 32 - 33, ISSN: 1359-6349, XP025026471 *

Also Published As

Publication number Publication date
WO2009109862A2 (fr) 2009-09-11

Similar Documents

Publication Publication Date Title
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
WO2010045318A3 (fr) Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
CY1124951T1 (el) Συνδυαστικη θεραπεια για την αντιμετωπιση των κακοηθειων
MX2015006939A (es) Tratamiento de cancer con inhibidores heterociclicos de glutaminasa.
WO2009044173A3 (fr) Procédés de traitement du cancer à l'aide d'inhibiteurs de la voie de notch
WO2012034116A3 (fr) Petites molécules à titre de modulateurs épigénétiques de la déméthylase 1 spécifique de la lysine et méthodes de traitement de troubles
WO2012006589A3 (fr) Procédés et compositions pour l'identification, l'évaluation et le traitement de cancers associés à des signaux hedgehog
BRPI0922301A2 (pt) combinações de inibidor de hsp90
MX2009009738A (es) Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
WO2011085039A3 (fr) Utilisation d'inhibiteurs de l'histone acétyltransférase en tant que nouvelles thérapies anticancéreuses
WO2011137320A3 (fr) Inhibiteurs de petites molécules de l'activité de l'enzyme de déubiquination usp1
WO2012068405A3 (fr) Modulation de l'expression de l'alpha synucléine
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
WO2009114475A3 (fr) Compositions comprenant de la pcsk9 humaine et un siarn d’apolipoprotéine b, et procédés d’utilisation de celles-ci
WO2008008923A3 (fr) Compositions et procédés pour cibler des complexes de transcription spécifiques du cancer
WO2010042933A3 (fr) Inhibition et traitement des métastases du cancer de la prostate
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
WO2011097582A3 (fr) Traitement de maladies liées à l'arachidonate 12-lipogénase du type 12r (alox12b) par l'inhibition du produit de la transcription antisens naturelle vers alox12b
GB2475660A (en) Methods and kits for treating cluster headache disorders
WO2012138789A3 (fr) Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
ATE534738T1 (de) Mir-126-regulierte gene und pfade als ziele für therapeutische interventionen
WO2009109862A3 (fr) Substances thérapeutiques anticancéreuses améliorées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09717469

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09717469

Country of ref document: EP

Kind code of ref document: A2